BMJ Open
July 1, 2026
Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.
INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...
Brain and Behavior
June 1, 2026
Aloysius Amos Lau, Shalini Arunogiri, Boen Raner-Galutera et al.
1 citation
Peer Support Workers (PSWs) in mental health and substance use treatment draw on their lived experience (LE) to support clients through mutual understanding and trust. Psychedelic-assisted therapy (PAT) is emerging as a mental health and substance use treatment modality. As interest grows, understanding PSWs' perspectives on PAT is critical to inform safe and effective implementation, and the...
Addiction (Abingdon, England)
March 30, 2026
Sarah J Catchlove, Katrin Oliver, Michael Savic et al.
Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
March 27, 2026
Kade L Huckstep, Billi Newton, Grace Bailey et al.
Comorbidity between post-traumatic stress disorder (PTSD) and alcohol use is common and mutually-reinforcing, yet there are no pharmacological strategies that specifically target trauma-linked escalation of alcohol intake. We evaluated whether 3,4-methylenedioxymethamphetamine (MDMA), given in a therapy-adjunctive fashion (30 min before fear extinction), could facilitate extinction of...
Aust N Z J Psychiatry
July 8, 2025
Zachary Bryant, Kirsten Morley, Eva Louie et al.
3 citations
What do clinicians think about psychedelic-assisted therapy? An Australian perspective.
The Australian and New Zealand journal of psychiatry
October 1, 2024
Alistair Carroll, Adam Bayes, Mark Montebello et al.
10 citations
Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...